Latest / The Well-Built Life / The Mystery of Biliary Atresia: A Journey Through Its Origins and Treatments
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:09Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:14Speaker 1: share simple practical habits that help you feel stronger, healthier,
- 0:18Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:23Speaker 1: and let's dive in. Hey, Thomas, let's dive into today's topic,
- 0:27Speaker 1: biliary atresia. It's a rare condition, but crucial to understand,
- 0:32Speaker 1: especially early diagnosis. What do you think is the first
- 0:36Speaker 1: thing we should cover?
- 0:37Speaker 2: Great idea, Rachel. Let's start with the basics. Biliary atresia
- 0:41Speaker 2: is an obstruction of the bile ducts, and it's crucial
- 0:44Speaker 2: to note that it can begin in utero or shortly
- 0:47Speaker 2: after birth. For those who might not be familiar, what
- 0:50Speaker 2: do you think about the fetal and perinatal types, and
- 0:53Speaker 2: how do they differ?
- 0:54Speaker 1: Exactly, and that's the crucial nuance here. The fetal type
- 0:58Speaker 1: is identified at birth with jaundice and other symptoms right away.
- 1:02Speaker 1: But the perinatal type is trickier. It presents later, around
- 1:05Speaker 1: two to six weeks after birth. Both types lead to
- 1:08Speaker 1: similar clinical outcomes, but the timing and mechanisms of obstruction
- 1:13Speaker 1: are different.
- 1:13Speaker 2: That's right, and it's fascinating how the fetal type begins
- 1:17Speaker 2: before birth, while the perinatal type is more elusive. When
- 1:21Speaker 2: you look at the mechanics, the fetal type is due
- 1:24Speaker 2: to improper development of bile ducts, but in the perinatal type,
- 1:28Speaker 2: the bile ducts develop normally and postnatal damage occurs. That's
- 1:32Speaker 2: a real contradiction, isn't it?
- 1:35Speaker 1: Oh, that's a great point, Thomas. The contradiction lies in
- 1:38Speaker 1: how these two types present such different timelines, but converge
- 1:42Speaker 1: on similar symptoms. It's like two different paths leading to
- 1:45Speaker 1: the same destination. Now, speaking of symptoms, can you elaborate
- 1:51Speaker 1: on the key clinical manifestations?
- 1:54Speaker 2: Sure. We start with jaundice, which is a yellowing of
- 1:57Speaker 2: the skin and eyes due to high levels of conjugated bilirubin.
- 2:01Speaker 2: This is often accompanied by dark urine and pale stools.
- 2:05Speaker 2: Pruritus or severe itching due to bile salts accumulating in
- 2:08Speaker 2: the skin and failure to thrive are also common. These
- 2:12Speaker 2: symptoms provide the first clues for diagnosis.
- 2:15Speaker 1: Exactly, and it brings up an interesting contradiction. While the
- 2:19Speaker 1: symptoms themselves are clear, the underlying mechanisms are still somewhat
- 2:24Speaker 1: of a mystery. For example, the role of viral infections
- 2:28Speaker 1: or environmental toxins in the perinatal type is still debated.
- 2:33Speaker 1: This complexity adds another layer to the condition.
- 2:36Speaker 2: True, and it's fascinating. Moving on to diagnosis, what are
- 2:40Speaker 2: the key steps and tools used to confirm biliary atresia?
- 2:43Speaker 1: Good question. Lab tests like high conjugated bilirubin levels, elevated
- 2:49Speaker 1: gamma-glutamyl transferase, and alkaline phosphatase, and imaging techniques such as
- 2:54Speaker 1: ultrasound and HIDA scans are used. The HIDA scan is
- 2:58Speaker 1: particularly useful due to its ability to show the absence
- 3:02Speaker 1: or abnormality of the gallbladder and the presence of the
- 3:05Speaker 1: triangular chord sign, which is a hallmark of biliary atresia.
- 3:09Speaker 2: And the final confirmation often comes from a liver biopsy,
- 3:13Speaker 2: which offers a definitive diagnosis. It's both diagnostic and therapeutic now,
- 3:18Speaker 2: as liver biopsy can also guide the need for surgical intervention.
- 3:23Speaker 2: Let's talk about the treatment, specifically the CASAI procedure. How
- 3:27Speaker 2: effective is it, and what are the long-term outcomes?
- 3:30Speaker 1: The CASAI procedure, also known as hepatoportuin terastomy, is a
- 3:35Speaker 1: crucial surgical intervention for early-stage extrapatic obstructions. While it can
- 3:41Speaker 1: greatly improve liver function, its success rate diminishes in advanced
- 3:45Speaker 1: cases with intrahepatic involvement. Liver transplantation might be necessary in
- 3:50Speaker 1: these more severe cases, as it can extend survival, but
- 3:54Speaker 1: comes with its own set of challenges.
- 3:56Speaker 2: Right, and that brings up the critical debate angle regarding
- 3:59Speaker 2: the long-term outcomes of liver transplantation. It's a high-cost procedure
- 4:04Speaker 2: with the need for lifelong immunosuppression, and the impact on
- 4:07Speaker 2: the quality of life for both the patients and their
- 4:10Speaker 2: caregivers is significant. It's a tough decision for any family.
- 4:14Speaker 1: Absolutely, and it's a topic we can definitely explore more
- 4:17Speaker 1: in future episodes. For now, let's conclude by touching on
- 4:21Speaker 1: the broader context of research, patient support, and public awareness.
- 4:26Speaker 1: What are your thoughts on these areas, Thomas?
- 4:28Speaker 2: Well, research is ongoing, focusing on identifying biomarkers for early
- 4:33Speaker 2: detection and more effective treatments. Patient support networks are essential
- 4:38Speaker 2: to providing comprehensive care and addressing the psychological and social
- 4:43Speaker 2: needs of both patients and their families. And public awareness
- 4:47Speaker 2: campaigns could go a long way in improving early diagnosis
- 4:50Speaker 2: and treatment outcomes.
- 4:52Speaker 1: Exactly, and that's a powerful way to end today's discussion.
- 4:56Speaker 1: Thanks for your insights, Thomas. We have covered a lot,
- 5:00Speaker 1: and hopefully our listeners now have a better understanding of
- 5:03Speaker 1: biliary atresia. Tune in next time. and let's explore more
- 5:08Speaker 1: medical mysteries.
- 5:09Speaker 2: Agreed, Rachel. See you then. Bye.
- 5:12Speaker 1: So, Thomas, let's delve into the developmental pathways of bile ducts. First,
- 5:18Speaker 1: how do hepatocytes play a critical role in this process?
- 5:21Speaker 2: Right, Rachel. Hepatocytes, the workhorses of the liver, are responsible
- 5:25Speaker 2: for producing bile. They mix bile salts, phospholipids, cholesterol, and
- 5:31Speaker 2: conjugated bilirubin to form this essential fluid. The bile then
- 5:35Speaker 2: flows through tiny channels called bile canaliculi, which merge to
- 5:40Speaker 2: form the intrahepatic bile ducts. These ducts eventually connect to
- 5:45Speaker 2: form the right and left hepatic ducts, which ultimately become
- 5:49Speaker 2: the common hepatic duct and merge with the cystic duct
- 5:53Speaker 2: to form the common bile duct.
- 5:54Speaker 1: Interesting. And what happens during the formation of these bile
- 5:59Speaker 1: ducts in the fetal type of biliary atresia?
- 6:02Speaker 2: In the fetal type The issue arises when these bile
- 6:05Speaker 2: ducts don't develop properly. During fetal development, to raise a
- 6:09Speaker 2: critical period where these channels are forming, any obstruction or
- 6:13Speaker 2: failure in this development can lead to improper bile drainage.
- 6:17Speaker 2: This triggers a ductular reaction where hepatocytes swell and degenerate,
- 6:22Speaker 2: leading to obstruction and fibrosis. It's like the liver cells
- 6:27Speaker 2: are trying to compensate, but end up creating scar tissue
- 6:30Speaker 2: around the bile ducts.
- 6:32Speaker 1: And what about the perinatal type? How does it differ
- 6:35Speaker 1: in terms of obstruction mechanisms?
- 6:38Speaker 2: In the perinatal type, the bile ducts develop normally, but unfortunately,
- 6:43Speaker 2: after birth, they get damaged. This can be due to
- 6:46Speaker 2: an infection or exposure to toxins. The result is the
- 6:50Speaker 2: destruction of cholangiocytes, the specialized cells that line the bile ducts.
- 6:55Speaker 2: This damage leads to obstruction, much like in the fetal type,
- 6:59Speaker 2: but the process is postnatal. It's a bit like the
- 7:02Speaker 2: liver trying to maintain its functions but getting sand in
- 7:05Speaker 2: the gears, leading to long-term issues.
- 7:07Speaker 1: Fascinating. And how does this obstruction and subsequent fibrosis lead
- 7:13Speaker 1: to biliary cirrhosis?
- 7:15Speaker 2: The ductular reaction and feathery degeneration of hepatocytes cause paraportal fibrosis.
- 7:21Speaker 2: Over time, this fibrosis spreads, forming bridges between liver lobules,
- 7:26Speaker 2: which is characteristic of cirrhosis. It's a slow, progressive process
- 7:31Speaker 2: where the liver's ability to function declines as the fibrosis
- 7:34Speaker 2: takes over more and more of its structure.
- 7:37Speaker 1: And what are some of the clinical signs we might
- 7:40Speaker 1: see in children with biliary atresia, particularly the perinatal type?
- 7:44Speaker 2: In the perinatal type, jaundice, dark urine, and pale stools
- 7:49Speaker 2: often appear between 2 to 6 weeks of age. These
- 7:53Speaker 2: clinical signs are due to the accumulation of conjugated bilirubin
- 7:56Speaker 2: in the blood. There is also pruritus, or itching, from
- 8:00Speaker 2: the bile salts in the skin and a failure to
- 8:03Speaker 2: thrive due to poor fat absorption. These symptoms really highlight
- 8:08Speaker 2: the importance of early diagnosis and intervention.
- 8:11Speaker 1: Definitely. So, what are the key treatment strategies for these infants?
- 8:17Speaker 2: Early intervention is crucial. The CASI procedure is used for
- 8:21Speaker 2: extrashepatic obstructions. This operation involves reconstructing the bile ducts to
- 8:26Speaker 2: allow bile to flow out of the liver. For advanced cases,
- 8:30Speaker 2: liver transplantation might be necessary. It's a complex journey with
- 8:34Speaker 2: many challenges, but the goal is to relieve the obstruction
- 8:38Speaker 2: and give the liver a chance to recover or be
- 8:40Speaker 2: replaced if needed.
- 8:41Speaker 1: So let's talk about the diagnostic tools used for biliary atresia.
- 8:46Speaker 1: We know that early detection is crucial. What do these
- 8:49Speaker 1: tools actually look like in practice?
- 8:52Speaker 2: Absolutely, Rachel. The first line of defense is typically a
- 8:55Speaker 2: series of lab tests that detect elevated levels of conjugated
- 8:59Speaker 2: bilirubin and bile acids. These tests can be a red flag,
- 9:03Speaker 2: but they certainly don't confirm biliary atresia. They are more
- 9:07Speaker 2: indicative of an issue, but not definitive. Right.
- 9:10Speaker 1: And that's the crucial nuance here. These lab tests are important.
- 9:15Speaker 1: but they are not where the rubber meets the road
- 9:17Speaker 1: when it comes to diagnosing biliary atresia. So, what do
- 9:22Speaker 1: imaging techniques like ultrasound and HIDA scans do for us?
- 9:26Speaker 2: Ultrasound is great for its simplicity and lack of invasiveness,
- 9:30Speaker 2: but it does have its limitations. It might miss early
- 9:33Speaker 2: stage cases or provide ambiguous results. The HIDA scan, on
- 9:38Speaker 2: the other hand, uses a radioactive dye that helps visualize
- 9:42Speaker 2: the biliary system. The triangular cord sign is a telltale
- 9:46Speaker 2: feature seen in cases of biliary atresia, where the gallbladder
- 9:50Speaker 2: remains absent or underdeveloped.
- 9:52Speaker 1: Exactly. And the HIDA scan is quite effective. But let's
- 9:56Speaker 1: dive into the intricacies. The triangular chord sign is a
- 10:00Speaker 1: specific indicator, but it's not always present. What about situations
- 10:05Speaker 1: where Terry's no clear sign?
- 10:07Speaker 2: That's where things get interesting. MRCP, or magnetic resonance cholangiopancreatophy,
- 10:13Speaker 2: is now becoming a more common tool. It's non-invasive and
- 10:17Speaker 2: can provide detailed images of the biliary tract, including small
- 10:21Speaker 2: bile ducts that might be missed by other imaging techniques.
- 10:25Speaker 2: It's like having a super zoom lens on your diagnostic toolkit.
- 10:29Speaker 1: That's a great point. So, MIST iHEM CP is really
- 10:33Speaker 1: stepping up its game, and we still have the old standby,
- 10:36Speaker 1: the liver biopsy. Can you tell us a little bit
- 10:39Speaker 1: more about its role?
- 10:40Speaker 2: The liver biopsy is definitely a last resort because it's invasive. However,
- 10:45Speaker 2: it's essential for confirming the diagnosis. The pathologist looks at
- 10:50Speaker 2: the tissue under a microscope and sees the ductular reaction
- 10:53Speaker 2: and progressive fibrosis. It's the definitive test, but it's invasive
- 10:58Speaker 2: and comes with some risks.
- 11:00Speaker 1: I see. So, as we are looking at these tools,
- 11:04Speaker 1: it's clear that a multifaceted approach is necessary. And each
- 11:08Speaker 1: tool has its place, but also its limitations. What about
- 11:12Speaker 1: the CASAI procedure? Is it ever used as a diagnostic tool?
- 11:16Speaker 2: The CASI procedure is more of a treatment than a diagnostic,
- 11:20Speaker 2: but it can help diagnose biliary atresia in some cases.
- 11:24Speaker 2: It involves creating an astimosis between the hepatic ducts and
- 11:27Speaker 2: the jejunum to bypass the obstruction. If the procedure is successful,
- 11:31Speaker 2: it suggests the presence of an extra-hepatic bile duct obstruction. However,
- 11:37Speaker 2: it's not a foolproof diagnostic tool and is often used
- 11:40Speaker 2: in conjunction with other methods.
- 11:42Speaker 1: That's insightful. So, we have a mix of non-invasive and
- 11:47Speaker 1: invasive tests, each with its strengths and limitations. It's a
- 11:51Speaker 1: balancing act to determine the best approach for each patient.
- 11:56Speaker 1: Thanks for walking us through this.
- 11:57Speaker 2: Anytime, Rachel, early diagnosis and intervention are the keys to
- 12:02Speaker 2: better outcomes in biliary atresia. Understanding these diagnostic tools is
- 12:07Speaker 2: crucial for both clinicians and patients.
- 12:09Speaker 1: So, Thomas … Let's get into the nitty-gritty of surgical
- 12:13Speaker 1: interventions like the CASI procedure and liver transplantation. How do
- 12:19Speaker 1: these treatments fare in the long term, especially when it
- 12:22Speaker 1: comes to the most common complications and side effects?
- 12:25Speaker 2: Great question, Rachel. The CASI procedure, also known as hepatoportuenterostomy,
- 12:31Speaker 2: is a surgery that creates a connection between the liver
- 12:34Speaker 2: and the intestines, bypassing the blocked bile duct. It's primarily
- 12:39Speaker 2: used for patients with early-stage fetal biliary atresia. However, its
- 12:43Speaker 2: success can be hit or miss.
- 12:45Speaker 1: Right. So, let's dig into the outcomes. Are the long-term
- 12:50Speaker 1: benefits of the CASAI procedure truly long-term? Or do patients
- 12:55Speaker 1: often require a liver transplant down the line?
- 12:58Speaker 2: Well, the CASAI procedure can be incredibly effective in the
- 13:02Speaker 2: short term, helping to prevent complications like liver failure. However
- 13:06Speaker 2: … Its success is largely dependent on how early the
- 13:10Speaker 2: procedure is performed. In cases where the obstruction is intrahepatic,
- 13:15Speaker 2: the outcome can be less favorable. Studies show that about
- 13:18Speaker 2: 30% of patients who undergo CASI can remain alive without
- 13:23Speaker 2: a transplant for at least 5 years. But this number
- 13:26Speaker 2: drops significantly in the long term.
- 13:29Speaker 1: That's a significant decline in survival rates. What about liver transplantation?
- 13:35Speaker 1: Are there any recent advancements that have improved the outcomes?
- 13:38Speaker 2: Liver transplantation is the definitive treatment for biliary atresia, especially
- 13:44Speaker 2: in advanced cases. It replaces the diseased liver with a
- 13:48Speaker 2: healthy donor liver, offering a chance for a complete cure.
- 13:51Speaker 2: The success rates have been improving, thanks to better surgical
- 13:55Speaker 2: techniques and immunosuppressive regimens to prevent organ rejection. According to
- 14:00Speaker 2: a study, the five-year survival rate after a transplant is
- 14:04Speaker 2: around 70-80%. Absolutely. The cost of a liver transplant and
- 14:09Speaker 2: the lifelong immunosuppressive therapy are significant hurdles. Patients and families
- 14:15Speaker 2: must navigate a complex healthcare system, often dealing with high
- 14:19Speaker 2: financial burdens. Additionally, the risk of complications from immunosuppressive drugs,
- 14:25Speaker 2: such as infections, can be concerning. True.
- 14:28Speaker 1: Let's talk about the impact on quality of life. With
- 14:32Speaker 1: surgeries like these, how do they affect a child's day-to-day
- 14:35Speaker 1: life and overall well-being?
- 14:37Speaker 2: It's a tough balance. While these procedures can improve liver function,
- 14:42Speaker 2: they don't address the underlying fibrosis and cirrhosis. Patients may
- 14:47Speaker 2: still suffer from complications like portal hypertension, and the need
- 14:51Speaker 2: for lifelong monitoring and management post-transplantation presents a significant challenge.
- 14:57Speaker 2: The quality of life for these children often involves strict
- 15:00Speaker 2: dietary restrictions, medical appointments, and ongoing psychological support.
- 15:06Speaker 1: It sounds like a relentless journey, but Terry's a glimmer
- 15:09Speaker 1: of hope, isn't there? What progress is being made in
- 15:12Speaker 1: terms of new treatment approaches or technologies?
- 15:15Speaker 2: Exactly, Rachel. Researchers are exploring non-invasive techniques like magnetic resonance cholangiopancreatography, mystography,
- 15:23Speaker 2: which can provide detailed images of the bile ducts without
- 15:27Speaker 2: the invasiveness of traditional imaging methods. Gene editing and stem
- 15:31Speaker 2: cell therapies are also being explored as potential treatments. These
- 15:35Speaker 2: advancements could offer less invasive alternatives and potentially even cure
- 15:40Speaker 2: some of the underlying causes of biliary atresia in the future.
- 15:44Speaker 1: That's exciting. It seems like Terry's still so much work
- 15:47Speaker 1: to be done, but the future looks promising. Thanks for
- 15:51Speaker 1: breaking it down, Thomas. Let's keep our fingers crossed for
- 15:55Speaker 1: continued advancements. So, let's dive into the origins of biliary atresia.
- 16:00Speaker 1: As you know, it begins with the hepatocytes, the liver's
- 16:03Speaker 1: primary cells, mixing bile ingredients. It's fascinating how these cells
- 16:09Speaker 1: create bile, which flows through the bile canaliculi.
- 16:13Speaker 2: Right? Exactly. And these canaliculi merge to form the intrahepatic
- 16:17Speaker 2: bile ducts, which eventually connect to the extrahetic biliary system.
- 16:22Speaker 2: culminating in the right and left hepatic ducts that merge
- 16:25Speaker 2: into the common hepatic duct. But in biliary atresia, this
- 16:29Speaker 2: process is disrupted.
- 16:30Speaker 1: Yes. Let's unpack this further. In fetal type, the key
- 16:34Speaker 1: issue is the failure of normal bile duct development. This
- 16:38Speaker 1: leads to a significant obstruction initiating a ductular reaction. This
- 16:43Speaker 1: reaction is characterized by hepatocyte swelling and destruction. then progressing
- 16:49Speaker 1: to feathery degeneration and periportal fibrosis.
- 16:52Speaker 2: Right. And as this fibrosis spreads, it eventually results in
- 16:56Speaker 2: biliary cirrhosis. It's a slow, progressive disease that can lead
- 17:00Speaker 2: to liver failure. Now, in the perinatal type, bile ducts
- 17:04Speaker 2: develop normally but get damaged postnatally, leading to cholangiocyte destruction
- 17:10Speaker 2: and obstruction.
- 17:11Speaker 1: That's correct. The clinical manifestations differ slightly between the two types.
- 17:16Speaker 1: For the fetal type, jaundice, Dark urine, pale stools, pruritus,
- 17:20Speaker 1: and failure to thrive are evident at birth. In the
- 17:24Speaker 1: perinatal type, these symptoms may not appear until two to
- 17:27Speaker 1: six weeks after birth.
- 17:29Speaker 2: And as the disease progresses, signs of liver failure such
- 17:33Speaker 2: as splenomegaly, hepatomegaly, and ascites develop. The diagnosis and treatment
- 17:39Speaker 2: involve a combination of laboratory tests, imaging techniques, and sometimes
- 17:43Speaker 2: liver biopsy. The CASI procedure is crucial for early-stage obstruction,
- 17:49Speaker 2: while liver transplantation may be necessary for advanced cases. That's true.
- 17:54Speaker 2: The role of the immune response in the perinatal type
- 17:56Speaker 2: is also a critical area of debate. Therese evidence pointing
- 18:00Speaker 2: to an immune-mediated mechanism, but the precise triggering factors are
- 18:04Speaker 2: still unknown.
- 18:05Speaker 1: And the genetic and environmental interaction is another hot topic.
- 18:10Speaker 1: Therese growing evidence of genetic predispositions. but the environmental triggers
- 18:15Speaker 1: are still being elucidated. Advances in imaging and genetic testing
- 18:20Speaker 1: could provide more precise diagnosis and treatment planning.
- 18:24Speaker 2: Definitely. And moving forward, we need to focus on research priorities,
- 18:28Speaker 2: patient support networks, and public awareness. Identifying biomarkers for early
- 18:33Speaker 2: detection and potential gene therapies could make a significant impact.
- 18:37Speaker 2: Improving surgical techniques and developing less invasive therapies are also crucial. Agreed.
- 18:44Speaker 1: The future outlook includes genetic research, immunological mechanisms, advanced imaging,
- 18:49Speaker 1: and treatment innovations. Implementing targeted screening programs and public awareness
- 18:55Speaker 1: campaigns could further improve early diagnosis and treatment outcomes.
- 18:59Speaker 2: Yes, and let's not forget the key quotes that summarize
- 19:02Speaker 2: these points. The hepatocytes mix several ingredients to create bile,
- 19:07Speaker 2: and without proper drainage, bile backs up, triggering a series
- 19:10Speaker 2: of events leading to cirrhosis and complications. Understanding these mechanisms
- 19:15Speaker 2: will be key to developing better treatments and care for
- 19:18Speaker 2: these infants.
- 19:19Speaker 1: That brings us to the end of today's episode. Thank
- 19:21Speaker 1: you so much for spending part of your day with me.
- 19:24Speaker 1: If you found this episode's tips helpful and want to
- 19:27Speaker 1: make sure you don't miss the next conversation, please take
- 19:30Speaker 1: a quick second to hit that subscribe or follow button
- 19:33Speaker 1: on whatever platform you are listening on. It's a completely
- 19:37Speaker 1: free way to support the show and helps more people
- 19:40Speaker 1: find us. This podcast is independently produced So if you
- 19:43Speaker 1: are ever in a position where you would like to
- 19:45Speaker 1: help keep it running, we do accept small donations. You
- 19:49Speaker 1: can find a link. right in the episode description below
- 19:51Speaker 1: to buy us a coffee or contribute what you can.
- 19:55Speaker 1: Every bit genuinely helps. Take care of yourself, stay balanced,
- 19:59Speaker 1: and we will talk again soon.